ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia
May 28, 2021Spruce Biosciences Inc. presented data from its Phase 2 clinical trial of tildacerfont in adults with classic congenital adrenal hyperplasia (CAH) at the European Society of Endocrinology’s 23rd European Congress of Endocrinology (ECE 2021). -
Spruce Biosciences Announces Positive Results from Tildacerfont Study
September 23, 2019Spruce Biosciences announced positive results from a Phase 2a, multicenter, 12-week trial of tildacerfont, an investigational, oral, once-a-day corticotropin-releasing factor type-1 receptor antagonist ...
Pharma Sources Insight January 2025
